Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.
Severe brain injury that develops slowly after preterm births, causing the likes of cerebral palsy, may be treatable, new research from the University of Auckland finds.
Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.
People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors -; a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions -; generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.
Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented today at EADV’s 30th Congress.
Uveitis is an inflammation of the eye and is a common extra-articular manifestation associated with juvenile idiopathic arthritis (JIA). It can cause vision-threatening complications, and if left uncontrolled may even lead to blindness.
Immune inflammatory mediators are critical in pathology, transplantation, and regenerative medicine, scientists report in The American Journal of Pathology
The monoclonal antibody secukinumab is approved for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of six years who are candidates for systemic therapy.
People suffering from rheumatoid arthritis with increased disease activity are more often affected by thrombosis.
Juvenile immune arthritis (JIA) is a severely undertreated condition, and new medications are badly needed to relieve the signs and symptoms of the illness, according to a new study presented at the 2019 ACR/ARP Annual Meeting.
A new study found that patients with Down syndrome arthropathy continue to have an approximate year-long delay in diagnosis from the onset of their symptoms, and that optimal therapy for this condition remains unclear.
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis, despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, the live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications.
There is a growing body of knowledge that points that type 2 diabetes, a chronic disease where the blood sugar increases, is an inflammatory disease. The levels of certain inflammatory chemicals, dubbed as cytokines, are often higher in people with type 2 diabetes, than healthy people.
A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.
Celecoxib combined with TNF inhibitors was associated with the greatest reduction in radiographic progression.
In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa.
The results of a study presented today at the Annual European Congress of Rheumatology 2017 have confirmed that Fluorescence Optical Imaging, a technique used to visualize inflammation in arthritic joints, is as effective as ultrasound with Power Doppler (US / PD) at monitoring response to treatment in juvenile idiopathic arthritis.
Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease. The team used sedimentation velocity analytical ultracentrifugation to investigate drug-target binding in a physiological environment and at clinically-relevant concentrations.
Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.
Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures.